BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Ember LifeSciences and Alfresa Corp to improve quality of pharmaceutical cold chain in Japan

August 1, 2026 | News

Alfresa will provide financial support for Ember's business expansion



Ember LifeSciences, Inc. has entered into a capital and business alliance with Alfresa Corporation, a subsidiary of Alfresa Holdings Corporation. Alfresa will partner with Ember to improve the quality of pharmaceutical cold chain logistics across Japan, including evaluating the Ember Cube and related technologies for Alfresa's Home Care Delivery service, which delivers specialty pharmaceuticals directly from medical institutions to patients' homes.

As part of the new alliance, Alfresa will provide financial support for Ember's business expansion through an investment in Series A preferred stock issued by Ember, strengthening collaboration between the two companies. Other investors in the Ember Series A include Amgen, Cardinal Health, Carrier and Sea Court Capital. Through the agreement, Alfresa obtains the exclusive sales rights in Japan's healthcare sector for solutions provided by Ember.

Ember provides pharmaceutical manufacturers, distributors and healthcare providers with cold chain solutions that combine temperature control with real-time shipment visibility. The Ember Cube 2, which recently earned the Best of the Best Red Dot Design Award, maintains a temperature range of 2°C to 8°C for more than 72 hours while continuously monitoring shipment conditions and location. Its reusable design also helps reduce packaging waste compared with traditional single-use shipping materials.